Myeloma XI Quadruplet regimen for transplant eligible patients shows promise
Myeloma XI: Quadruplet regimen for transplant eligible patients shows promise
Hope has emerged for patients with a serious type of bone marrow cancer as new research into a therapeutic drug has revealed improved outcomes and survival rates.
In the largest study of its kind, researchers at Newcastle University, UK, have led...
More From BioPortfolio on "Myeloma XI: Quadruplet regimen for transplant eligible patients shows promise"